US Patent

US8829186 — Method for preparation of pitavastatin and pharmaceutical acceptable salts thereof

Composition of Matter · Assigned to Cadila Healthcare Ltd · Expires 2031-01-19 · 5y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a method for preparing pitavastatin and its pharmaceutical acceptable salts, specifically salts of magnesium, zinc, potassium, strontium, and barium.

USPTO Abstract

The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.

Drugs covered by this patent

pitavastatin-magnesium (PITAVASTATIN MAGNESIUM)

Patent Metadata

Patent number: US8829186
Jurisdiction: US
Classification: Composition of Matter
Expires: 2031-01-19
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Cadila Healthcare Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.